Sung Ho Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sung Ho Lee has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Won-Sang Cho
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
15 shared publications - Kang Min Kim
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
11 shared publications - Jeong Eun Kim
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
10 shared publications Hyun-Seung Kang
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
8 shared publications- Hyun-Seung Kang
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
8 shared publications Jeong Eun Kim
Seoul National University Hospital
7 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (2) , 215-224
Timing for the Resumption of Anticoagulants after Intracranial Hemorrhage
Objective : To identify the ideal timing for resuming oral or injectable anticoagulants therapy after spontaneous intracranial hemorrhage (sICH).Methods : We conducted a retrospective cohort study involving 90 patients from a tertiary hospital in Korea, between June 2000 and May 2022, who had experienced sICH while receiving anticoagulant therapy and who resumed treatment within 6 months. Exclusions were made for trauma-induced hemorrhages and early post-ictus fatalities. The interval between sICH occurrence and anticoagulant resumption was the main exposure variable. We evaluated hemorrhagic and thromboembolic events as outcomes. Multivariate analysis was used to determine the risk factors for post-resumption complications. Receiver operating characteristic (ROC) and locally estimated scatterplot smoothing (LOESS) were used to identify optimal timing.Results : The median patient age was 71 years, with 56.7% male. Warfarin was the most commonly used anticoagulant prior to sICH (63.3%), and non-vitamin K antagonist oral anticoagulants (NOACs) were used in 22.2%. Within 6 months of resuming anticoagulants, nine patients experienced hemorrhagic and 13 experienced ischemic complications. Age ≥80 years was significantly associated with ischemic events (odds ratio [OR], 4.29; p=0.048), while NOAC use was strongly associated with hemorrhagic complications (OR, 16.59; p=0.003). ROC analyses suggested possible cut-off points for anticoagulants resumption at day 30 for ischemic risk and day 7.5 for hemorrhagic risk, though AUC values were not statistically significant. Risk modeling using LOESS curves indicated that the combined complication risk was lowest when anticoagulants were resumed between days 20 and 22 after ictus.Conclusion : The findings suggest that approximately 3 weeks after sICH is the optimal time to resume anticoagulants, minimizing the risk of rebleeding or thromboembolic events. These findings may inform clinical decision-making in a broad patient population, though individualized assessment remains essential.
- 1 March 2026
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 69 (2) , 215-224
Open AccessTiming for the Resumption of Anticoagulants after Intracranial Hemorrhage
Objective : To identify the ideal timing for resuming oral or injectable anticoagulants therapy after spontaneous intracranial hemorrhage (sICH).Methods : We conducted a retrospective cohort study involving 90 patients from a tertiary hospital in Korea, between June 2000 and May 2022, who had experienced sICH while receiving anticoagulant therapy and who resumed treatment within 6 months. Exclusions were made for trauma-induced hemorrhages and early post-ictus fatalities. The interval between sICH occurrence and anticoagulant resumption was the main exposure variable. We evaluated hemorrhagic and thromboembolic events as outcomes. Multivariate analysis was used to determine the risk factors for post-resumption complications. Receiver operating characteristic (ROC) and locally estimated scatterplot smoothing (LOESS) were used to identify optimal timing.Results : The median patient age was 71 years, with 56.7% male. Warfarin was the most commonly used anticoagulant prior to sICH (63.3%), and non-vitamin K antagonist oral anticoagulants (NOACs) were used in 22.2%. Within 6 months of resuming anticoagulants, nine patients experienced hemorrhagic and 13 experienced ischemic complications. Age ≥80 years was significantly associated with ischemic events (odds ratio [OR], 4.29; p=0.048), while NOAC use was strongly associated with hemorrhagic complications (OR, 16.59; p=0.003). ROC analyses suggested possible cut-off points for anticoagulants resumption at day 30 for ischemic risk and day 7.5 for hemorrhagic risk, though AUC values were not statistically significant. Risk modeling using LOESS curves indicated that the combined complication risk was lowest when anticoagulants were resumed between days 20 and 22 after ictus.Conclusion : The findings suggest that approximately 3 weeks after sICH is the optimal time to resume anticoagulants, minimizing the risk of rebleeding or thromboembolic events. These findings may inform clinical decision-making in a broad patient population, though individualized assessment remains essential.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Clinical Neurology
- Vol. 22 (2) , 160-172
Whole-Exome Sequencing Improves Risk Assessments of Adult Moyamoya Disease
Hong EP, et al. J Clin Neurol. 2026 Jan;22:e13. https://doi.org/10.3988/jcn.2025.0482
- 1 January 2026
- Published by XMLink in Journal of Clinical Neurology
- Vol. 22 (2) , 160-172
Open AccessWhole-Exome Sequencing Improves Risk Assessments of Adult Moyamoya Disease
Hong EP, et al. J Clin Neurol. 2026 Jan;22:e13. https://doi.org/10.3988/jcn.2025.0482
- 26 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (8) , 1159-1169
Risk of peripartum cerebrovascular events in women with moyamoya disease: A multicenter cohort study
Background: Pregnancy and delivery are known to increase the risk of cerebrovascular events (CVEs) in patients with moyamoya disease (MMD). This study determined the frequency, risk factors, and outcome of CVEs during pregnancy in MMD. Methods: We conducted a multicenter study involving 171 MMD patients with 196 deliveries across four Korean tertiary institutions between 1990 and 2023. Data on MMD-related clinical, imaging, and operative findings were collected. We analyzed CVEs and pregnancy outcomes, including delivery mode and anesthesia. Univariate and multivariate analyses were performed to identify risk factors for peripartum CVEs. Results: Peripartum CVEs occurred in 5.6% of pregnancies, with intracerebral hemorrhage being the most common, followed by cerebral infarction. CVEs were more common in women diagnosed with MMD during pregnancy (85.7% vs. 2.6% in women diagnosed before pregnancy) and in women who had not completed revascularization before pregnancy or were hemodynamically unstable: 55.6% versus 1.1%. Delivery mode and anesthesia showed no significant association with the occurrence of CVEs. Multivariate analysis revealed that the “non-revascularized or hemodynamically unstable” group remained a significant risk factor for peripartum CVEs (adjusted odds ratio (OR) = 353.23, P < 0.001). CVEs resulted in maternal functional impairment in 4 of 11 affected cases (36.4%) and fetal loss in 2 of 11 cases (18.2%). Conclusion: This study highlights the protective effect of revascularization on peripartum CVEs and proposes a structured clinical protocol, recommending prepregnancy hemodynamic assessment and neurosurgical consultation. Women diagnosed with MMD during pregnancy and those in the “non-revascularized or hemodynamically unstable” group should be considered a high-risk group for peripartum CVEs.
- 26 November 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (8) , 1159-1169
Risk of peripartum cerebrovascular events in women with moyamoya disease: A multicenter cohort study
Background: Pregnancy and delivery are known to increase the risk of cerebrovascular events (CVEs) in patients with moyamoya disease (MMD). This study determined the frequency, risk factors, and outcome of CVEs during pregnancy in MMD. Methods: We conducted a multicenter study involving 171 MMD patients with 196 deliveries across four Korean tertiary institutions between 1990 and 2023. Data on MMD-related clinical, imaging, and operative findings were collected. We analyzed CVEs and pregnancy outcomes, including delivery mode and anesthesia. Univariate and multivariate analyses were performed to identify risk factors for peripartum CVEs. Results: Peripartum CVEs occurred in 5.6% of pregnancies, with intracerebral hemorrhage being the most common, followed by cerebral infarction. CVEs were more common in women diagnosed with MMD during pregnancy (85.7% vs. 2.6% in women diagnosed before pregnancy) and in women who had not completed revascularization before pregnancy or were hemodynamically unstable: 55.6% versus 1.1%. Delivery mode and anesthesia showed no significant association with the occurrence of CVEs. Multivariate analysis revealed that the “non-revascularized or hemodynamically unstable” group remained a significant risk factor for peripartum CVEs (adjusted odds ratio (OR) = 353.23, P < 0.001). CVEs resulted in maternal functional impairment in 4 of 11 affected cases (36.4%) and fetal loss in 2 of 11 cases (18.2%). Conclusion: This study highlights the protective effect of revascularization on peripartum CVEs and proposes a structured clinical protocol, recommending prepregnancy hemodynamic assessment and neurosurgical consultation. Women diagnosed with MMD during pregnancy and those in the “non-revascularized or hemodynamically unstable” group should be considered a high-risk group for peripartum CVEs.
- Open Access
- 25 November 2025
- Published by Springer Nature in Research Square
Efficacy of 3D-printed brain model for the simulation of external ventricular drainage
Purpose: Three-dimensional (3D)-printed brain models for neurosurgical training are gaining popularity. This study aimed to evaluate the educational efficacy of a 3D-printed model designed specifically for external ventricular drainage (EVD) training for neurosurgical residents. Methods: A prospective study involving neurosurgical residents was conducted between March 2024 and March 2025. A total of 18 residents were involved (n = 10 in Kocher’s point group and n = 8 in the Frazier’s point group). Procedural accuracy, time, and proficiency were assessed, along with surveys, to evaluate the educational efficacy of the model. Results: Significant improvements were noted in procedural performance between the first and second simulations in terms of burr hole location, time taken for burr hole trephination and ventriculostomy, as well as overall proficiency. Residents in the Kocher’s point group showed improvements in burr hole location (p = 0.025), burr hole trephination time (mean reduction of 39.2 seconds, p = 0.003), ventriculostomy time (mean reduction of 70.6 seconds, p = 0.002), and overall proficiency (p = 0.034). The Frazier’s point group improved in burr hole trephination time (mean reduction of 37.6 seconds, p = 0.041), EVD placement accuracy (p = 0.014), and overall proficiency (p = 0.014). Surveys indicated strong residents’ satisfaction (median score 5) and high faculty rating regarding anatomical resemblance (median scores 4–5). Conclusions: In this study, the 3D-printed EVD training model significantly enhanced neurosurgical residents’ procedural skills. The result suggests substantial educational value and potential of the model as a practical alternative to traditional cadaveric training methods.
- 25 November 2025
- Published by Springer Nature in Research Square
Open AccessEfficacy of 3D-printed brain model for the simulation of external ventricular drainage
Purpose: Three-dimensional (3D)-printed brain models for neurosurgical training are gaining popularity. This study aimed to evaluate the educational efficacy of a 3D-printed model designed specifically for external ventricular drainage (EVD) training for neurosurgical residents. Methods: A prospective study involving neurosurgical residents was conducted between March 2024 and March 2025. A total of 18 residents were involved (n = 10 in Kocher’s point group and n = 8 in the Frazier’s point group). Procedural accuracy, time, and proficiency were assessed, along with surveys, to evaluate the educational efficacy of the model. Results: Significant improvements were noted in procedural performance between the first and second simulations in terms of burr hole location, time taken for burr hole trephination and ventriculostomy, as well as overall proficiency. Residents in the Kocher’s point group showed improvements in burr hole location (p = 0.025), burr hole trephination time (mean reduction of 39.2 seconds, p = 0.003), ventriculostomy time (mean reduction of 70.6 seconds, p = 0.002), and overall proficiency (p = 0.034). The Frazier’s point group improved in burr hole trephination time (mean reduction of 37.6 seconds, p = 0.041), EVD placement accuracy (p = 0.014), and overall proficiency (p = 0.014). Surveys indicated strong residents’ satisfaction (median score 5) and high faculty rating regarding anatomical resemblance (median scores 4–5). Conclusions: In this study, the 3D-printed EVD training model significantly enhanced neurosurgical residents’ procedural skills. The result suggests substantial educational value and potential of the model as a practical alternative to traditional cadaveric training methods.
- Open Access
- 1 July 2025
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (4) , 392-404
Comparison of Clazosentan and Nimodipine on Vasospasm and Vasospasm-Related Outcomes after Aneurysmal Subarachnoid Hemorrhage : A Post-hoc Propensity Score-Matched Analysis of Six Randomized Clinical Trials
Objective : Clazosentan is a recently approved endothelin receptor antagonist indicated for the prevention of vasospasm and related complications following aneurysmal subarachnoid hemorrhage (aSAH). To date, no direct, head-to-head comparison between clazosentan and nimodipine has been conducted. In this study, we indirectly assessed the efficacy and safety of these two drugs in preventing vasospasm and its associated outcomes after aSAH.Methods : Participants from six randomized clinical trials of clazosentan were reclassified into three subgroups based on their concomitant use of oral nimodipine : 1) a clazosentan subgroup (without nimodipine), 2) a nimodipine subgroup (without clazosentan), and 3) a placebo subgroup (receiving neither clazosentan nor nimodipine). Data from participants who received the approved dose of clazosentan 10 mg/h was analyzed. To account for heterogeneities among the analyzed studies, we performed within-study comparisons of subgroups and pooled data from the same subgroup. To further balance the three groups, we conducted a propensity score-matching and compared the outcomes among subgroups. The outcomes measured were angiographic vasospasm within 14 days after aSAH and vasospasm-related morbidity and all-cause mortality (MM) within 6 weeks, defined as death, vasospasm-related new cerebral infarcts, delayed ischemic neurological deficits, or initiation of rescue therapy. Incidence and relative risk reduction (RRR) were analyzed across subgroups, and overall safety was reviewed.Results : The pooled data from within-study comparisons demonstrated that clazosentan significantly reduced the risk of vasospasm (RRR, 0.48; 95% confidence interval [CI], 0.35 to 0.58) and MM (RRR, 0.47; 95% CI, 0.30 to 0.60) compared to placebo, whereas nimodipine did not. In the propensity score-matched analysis, clazosentan demonstrated a significant risk reduction in outcomes when compared to nimodipine (RRR, 0.63; 95% CI, 0.46 to 0.75 for vasospasm; RRR, 0.29; 95% CI, 0.04 to 0.48 for MM) and placebo (RRR, 0.59; 95% CI, 0.40 to 0.72 for vasospasm; RRR, 0.41; 95% CI, 0.21 to 0.56 for MM).The overall safety results were comparable across the three subgroups and consistent with the expected range for endothelin receptor antagonists.Conclusion : Clazosentan at 10 mg/h significantly reduced the incidence of cerebral vasospasm and MM following aSAH, compared to both placebo and nimodipine. Further clinical studies are warranted to compare the efficacy of clazosentan and nimodipine to optimize treatment strategies for aSAH.
- 1 July 2025
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (4) , 392-404
Open AccessComparison of Clazosentan and Nimodipine on Vasospasm and Vasospasm-Related Outcomes after Aneurysmal Subarachnoid Hemorrhage : A Post-hoc Propensity Score-Matched Analysis of Six Randomized Clinical Trials
Objective : Clazosentan is a recently approved endothelin receptor antagonist indicated for the prevention of vasospasm and related complications following aneurysmal subarachnoid hemorrhage (aSAH). To date, no direct, head-to-head comparison between clazosentan and nimodipine has been conducted. In this study, we indirectly assessed the efficacy and safety of these two drugs in preventing vasospasm and its associated outcomes after aSAH.Methods : Participants from six randomized clinical trials of clazosentan were reclassified into three subgroups based on their concomitant use of oral nimodipine : 1) a clazosentan subgroup (without nimodipine), 2) a nimodipine subgroup (without clazosentan), and 3) a placebo subgroup (receiving neither clazosentan nor nimodipine). Data from participants who received the approved dose of clazosentan 10 mg/h was analyzed. To account for heterogeneities among the analyzed studies, we performed within-study comparisons of subgroups and pooled data from the same subgroup. To further balance the three groups, we conducted a propensity score-matching and compared the outcomes among subgroups. The outcomes measured were angiographic vasospasm within 14 days after aSAH and vasospasm-related morbidity and all-cause mortality (MM) within 6 weeks, defined as death, vasospasm-related new cerebral infarcts, delayed ischemic neurological deficits, or initiation of rescue therapy. Incidence and relative risk reduction (RRR) were analyzed across subgroups, and overall safety was reviewed.Results : The pooled data from within-study comparisons demonstrated that clazosentan significantly reduced the risk of vasospasm (RRR, 0.48; 95% confidence interval [CI], 0.35 to 0.58) and MM (RRR, 0.47; 95% CI, 0.30 to 0.60) compared to placebo, whereas nimodipine did not. In the propensity score-matched analysis, clazosentan demonstrated a significant risk reduction in outcomes when compared to nimodipine (RRR, 0.63; 95% CI, 0.46 to 0.75 for vasospasm; RRR, 0.29; 95% CI, 0.04 to 0.48 for MM) and placebo (RRR, 0.59; 95% CI, 0.40 to 0.72 for vasospasm; RRR, 0.41; 95% CI, 0.21 to 0.56 for MM).The overall safety results were comparable across the three subgroups and consistent with the expected range for endothelin receptor antagonists.Conclusion : Clazosentan at 10 mg/h significantly reduced the incidence of cerebral vasospasm and MM following aSAH, compared to both placebo and nimodipine. Further clinical studies are warranted to compare the efficacy of clazosentan and nimodipine to optimize treatment strategies for aSAH.
- Open Access
- 1 March 2025
- Published by AIP Publishing in AIP Advances
- Vol. 15 (3)
Expeditious synthesis of carbon nanotubes by localized and high-frequency induction heating system for enhanced field emission characteristics
This study demonstrates rapid carbon nanotube (CNT) synthesis using a 150 kHz induction heating system, enabling precise temperature and pressure control in thermal chemical vapor deposition processes. CNT growth optimization at temperatures between 887 and 955 °C and pressures from 1 to 700 Torr reveals that an optimized temperature (887 °C) and pressure (100 Torr) yield enhanced field emission performance. The 150 kHz induction heating provided faster heating rates and a more consistent temperature distribution across the substrate, significantly enhancing growth efficiency. CNT grown using the induction heating system demonstrated high emission currents and outstanding stability during field emission tests. The induction heating approach reduces synthesis time, offering an efficient pathway for scalable production of field emission devices.
- 1 March 2025
- Published by AIP Publishing in AIP Advances
- Vol. 15 (3)
Open AccessExpeditious synthesis of carbon nanotubes by localized and high-frequency induction heating system for enhanced field emission characteristics
This study demonstrates rapid carbon nanotube (CNT) synthesis using a 150 kHz induction heating system, enabling precise temperature and pressure control in thermal chemical vapor deposition processes. CNT growth optimization at temperatures between 887 and 955 °C and pressures from 1 to 700 Torr reveals that an optimized temperature (887 °C) and pressure (100 Torr) yield enhanced field emission performance. The 150 kHz induction heating provided faster heating rates and a more consistent temperature distribution across the substrate, significantly enhancing growth efficiency. CNT grown using the induction heating system demonstrated high emission currents and outstanding stability during field emission tests. The induction heating approach reduces synthesis time, offering an efficient pathway for scalable production of field emission devices.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (29) , e171
Trends in Incidences, Treatments and Outcomes of Spontaneous Subarachnoid Hemorrhage in Korea Between 2002 and 2022
Park J, et al. J Korean Med Sci. 2025 Jun;40:e171. https://doi.org/10.3346/jkms.2025.40.e171
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (29) , e171
Open AccessTrends in Incidences, Treatments and Outcomes of Spontaneous Subarachnoid Hemorrhage in Korea Between 2002 and 2022
Park J, et al. J Korean Med Sci. 2025 Jun;40:e171. https://doi.org/10.3346/jkms.2025.40.e171
- Open Access
- 1 May 2024
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
A Common Data Model for Oral Anticoagulants-related Risk of Spontaneous Intracranial Hemorrhage (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Spontaneous intracranial hemorrhage (sICH) is a major complication associated with oral anticoagulation which results in a high mortality rate, and the incidence of anticoagulant-induced sICH has increased markedly, so it is necessary to investigate the risk of anticoagulation-related sICH in a real-world setting. Objective: We aimed to investigate the incidence and risk factors of oral anticoagulant-related sICH using a common data model (CDM), and to determine whether a clinical study using the CDM would be comparable to conventional studies. Methods: After converting the various clinical codes of 12,821 patients taking oral anticoagulants, such as warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), into the Observational Medical Outcomes Partnership (OMOP) CDM format, we analyzed the incidence and risk factors of sICH. Results: sICH occurred in 0.5% of 5,626 patients with warfarin and 0.2% of 7,195 patients with NOAC. The mean duration of warfarin and NOACs before sICH occurrence was 251.4 ± 373.6 and 124.2 ± 135.7 days, respectively. Multivariable analysis showed significant risk factors of the sICH, such as warfarin over NOACs; hypertension; diabetes mellitus; brain tumors; and decreased duration of oral anticoagulation. Conclusions: NOAC demonstrated a lower risk of sICH than warfarin in a real-world setting using OMOP CDM confined to a single institution. Clinical studies using a CDM for the multicenter datasets may provide more reliable information about the risk of sICH.
- 1 May 2024
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
Open AccessA Common Data Model for Oral Anticoagulants-related Risk of Spontaneous Intracranial Hemorrhage (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Spontaneous intracranial hemorrhage (sICH) is a major complication associated with oral anticoagulation which results in a high mortality rate, and the incidence of anticoagulant-induced sICH has increased markedly, so it is necessary to investigate the risk of anticoagulation-related sICH in a real-world setting. Objective: We aimed to investigate the incidence and risk factors of oral anticoagulant-related sICH using a common data model (CDM), and to determine whether a clinical study using the CDM would be comparable to conventional studies. Methods: After converting the various clinical codes of 12,821 patients taking oral anticoagulants, such as warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), into the Observational Medical Outcomes Partnership (OMOP) CDM format, we analyzed the incidence and risk factors of sICH. Results: sICH occurred in 0.5% of 5,626 patients with warfarin and 0.2% of 7,195 patients with NOAC. The mean duration of warfarin and NOACs before sICH occurrence was 251.4 ± 373.6 and 124.2 ± 135.7 days, respectively. Multivariable analysis showed significant risk factors of the sICH, such as warfarin over NOACs; hypertension; diabetes mellitus; brain tumors; and decreased duration of oral anticoagulation. Conclusions: NOAC demonstrated a lower risk of sICH than warfarin in a real-world setting using OMOP CDM confined to a single institution. Clinical studies using a CDM for the multicenter datasets may provide more reliable information about the risk of sICH.
- Open Access
- 1 May 2024
- Published by JMIR Publications Inc. in JMIR Preprints
A Common Data Model for Oral Anticoagulants-related Risk of Spontaneous Intracranial Hemorrhage (Preprint)
BACKGROUND Spontaneous intracranial hemorrhage (sICH) is a major complication associated with oral anticoagulation which results in a high mortality rate, and the incidence of anticoagulant-induced sICH has increased markedly, so it is necessary to investigate the risk of anticoagulation-related sICH in a real-world setting. OBJECTIVE We aimed to investigate the incidence and risk factors of oral anticoagulant-related sICH using a common data model (CDM), and to determine whether a clinical study using the CDM would be comparable to conventional studies. METHODS After converting the various clinical codes of 12,821 patients taking oral anticoagulants, such as warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), into the Observational Medical Outcomes Partnership (OMOP) CDM format, we analyzed the incidence and risk factors of sICH. RESULTS sICH occurred in 0.5% of 5,626 patients with warfarin and 0.2% of 7,195 patients with NOAC. The mean duration of warfarin and NOACs before sICH occurrence was 251.4 ± 373.6 and 124.2 ± 135.7 days, respectively. Multivariable analysis showed significant risk factors of the sICH, such as warfarin over NOACs; hypertension; diabetes mellitus; brain tumors; and decreased duration of oral anticoagulation. CONCLUSIONS NOAC demonstrated a lower risk of sICH than warfarin in a real-world setting using OMOP CDM confined to a single institution. Clinical studies using a CDM for the multicenter datasets may provide more reliable information about the risk of sICH.
- 1 May 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Common Data Model for Oral Anticoagulants-related Risk of Spontaneous Intracranial Hemorrhage (Preprint)
BACKGROUND Spontaneous intracranial hemorrhage (sICH) is a major complication associated with oral anticoagulation which results in a high mortality rate, and the incidence of anticoagulant-induced sICH has increased markedly, so it is necessary to investigate the risk of anticoagulation-related sICH in a real-world setting. OBJECTIVE We aimed to investigate the incidence and risk factors of oral anticoagulant-related sICH using a common data model (CDM), and to determine whether a clinical study using the CDM would be comparable to conventional studies. METHODS After converting the various clinical codes of 12,821 patients taking oral anticoagulants, such as warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), into the Observational Medical Outcomes Partnership (OMOP) CDM format, we analyzed the incidence and risk factors of sICH. RESULTS sICH occurred in 0.5% of 5,626 patients with warfarin and 0.2% of 7,195 patients with NOAC. The mean duration of warfarin and NOACs before sICH occurrence was 251.4 ± 373.6 and 124.2 ± 135.7 days, respectively. Multivariable analysis showed significant risk factors of the sICH, such as warfarin over NOACs; hypertension; diabetes mellitus; brain tumors; and decreased duration of oral anticoagulation. CONCLUSIONS NOAC demonstrated a lower risk of sICH than warfarin in a real-world setting using OMOP CDM confined to a single institution. Clinical studies using a CDM for the multicenter datasets may provide more reliable information about the risk of sICH.
- Open Access
- 1 March 2024
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 67 (2) , 146-157
Neovascularization in Outer Membrane of Chronic Subdural Hematoma : A Rationale for Middle Meningeal Artery Embolization
Objective : Chronic subdural hematomas (cSDHs) are generally known to result from traumatic tears of bridging veins. However, the causes of repeat spontaneous cSDHs are still unclear. We investigated the changes in vasculature in the human dura mater and outer membrane (OM) of cSDHs to elucidate the cause of their spontaneous repetition.Methods : The dura mater was obtained from a normal control participant and a patient with repeat spontaneous cSDHs. The pathological samples from the patient included the dura mater and OM tightly adhered to the inner dura. The samples were analyzed with a particular focus on blood and lymphatic vessels by immunohistochemistry, 3-dimensional imaging using a transparent tissue clearing technique, and electron microscopy.Results : The dural border cell (DBC) layer of the dura mater and OM were histologically indistinguishable. There were 5.9 times more blood vessels per unit volume of tissue in the DBC layer and OM in the patient than in the normal control. The DBC layer and OM contained pathological sinusoidal capillaries not observed in the normal tissue; these capillaries were connected to the middle meningeal arteries via penetrating arteries. In addition, marked lymphangiogenesis in the periosteal and meningeal layers was observed in the patient with cSDHs.Conclusion : Neovascularization in the OM seemed to originate from the DBC layer; this is a potential cause of repeat spontaneous cSDHs. Embolization of the meningeal arteries to interrupt the blood supply to pathological capillaries via penetrating arteries may be an effective treatment option.
- 1 March 2024
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 67 (2) , 146-157
Open AccessNeovascularization in Outer Membrane of Chronic Subdural Hematoma : A Rationale for Middle Meningeal Artery Embolization
Objective : Chronic subdural hematomas (cSDHs) are generally known to result from traumatic tears of bridging veins. However, the causes of repeat spontaneous cSDHs are still unclear. We investigated the changes in vasculature in the human dura mater and outer membrane (OM) of cSDHs to elucidate the cause of their spontaneous repetition.Methods : The dura mater was obtained from a normal control participant and a patient with repeat spontaneous cSDHs. The pathological samples from the patient included the dura mater and OM tightly adhered to the inner dura. The samples were analyzed with a particular focus on blood and lymphatic vessels by immunohistochemistry, 3-dimensional imaging using a transparent tissue clearing technique, and electron microscopy.Results : The dural border cell (DBC) layer of the dura mater and OM were histologically indistinguishable. There were 5.9 times more blood vessels per unit volume of tissue in the DBC layer and OM in the patient than in the normal control. The DBC layer and OM contained pathological sinusoidal capillaries not observed in the normal tissue; these capillaries were connected to the middle meningeal arteries via penetrating arteries. In addition, marked lymphangiogenesis in the periosteal and meningeal layers was observed in the patient with cSDHs.Conclusion : Neovascularization in the OM seemed to originate from the DBC layer; this is a potential cause of repeat spontaneous cSDHs. Embolization of the meningeal arteries to interrupt the blood supply to pathological capillaries via penetrating arteries may be an effective treatment option.